On April 6th, CBD manufacturer Ispire Technology Inc. (NASDAQ: ISPR) announced the completion of its initial public offering (IPO), issuing 2.7 million common shares at a price of $7.00 per share. The total amount raised from the offering was approximately $18.9 million (approximately RMB 130 million), not including underwriting discounts and commissions and estimated offering expenses.
This common stock began trading on the Nasdaq Capital Market on April 4. Additionally, two selling shareholders are able to offer 1.75 million shares of common stock according to the prospectus.
According to previous reports, the funds raised from this issuance will be used for:
Approximately 35% of the budget is allocated towards expanding manufacturing operations in Vietnam and the United States. Around 25% is dedicated to research and development activities, including the creation of new products and e-cigarette technologies. Approximately 20% is allocated towards marketing and promoting the company's branded products. The remaining 20% is set aside for general administrative and operational expenses.
Related Reading:
CBD manufacturer Ispire announces IPO pricing at $7 per share, issuing 2.7 million shares.
Reference:
Ispire Technology Inc. has announced the completion of its initial public offering.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
